Circulating miR-148a-3p Correlates with Inadequate Induction Response in Pediatric Hodgkin Lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Biomarkers

Background:

• Pediatric Hodgkin lymphoma (HL) is highly curable, necessitating treatment de-escalation to minimize long-term effects.
• Identifying biomarkers for treatment response at diagnosis is crucial for personalized therapy in pediatric HL.
• Circulating microRNAs (miRNAs) show potential as noninvasive biomarkers for therapeutic response in hematological cancers.

Purpose of the Study:

• To investigate the potential of circulating miRNAs to predict early metabolic response to induction therapy in pediatric Hodgkin lymphoma.
• To identify specific miRNAs associated with treatment response in pediatric HL patients.

Main Methods:

• Small RNA sequencing was performed on serum samples from 35 pediatric HL patients.
• Differential expression analysis identified Hodgkin lymphoma-associated miRNAs.
• Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used for validation of candidate miRNAs.

Main Results:

• Twenty-four Hodgkin lymphoma-associated miRNAs were differentially expressed between adequate and inadequate responders.
• Significantly elevated levels of miR‑148a‑3p were observed at diagnosis in patients with an inadequate response to induction therapy (p=0.009).

Conclusions:

• Circulating miR‑148a‑3p may serve as a predictive biomarker for early treatment response in pediatric Hodgkin lymphoma.
• This miRNA can potentially enhance current predictive strategies by identifying high-risk patients who may not achieve rapid metabolic remission.